NRSNW · NeuroSense Therapeutics Ltd.

This is a HIGH materiality event because continued Nasdaq listing is foundational to liquidity, institutional eligibility, and investor access. Failure to regain compliance by September 29, 2026 could result in delisting, triggering mandatory shareholder votes, potential transfer to OTC markets, and severe restrictions on capital raising and analyst coverage. The dual deficiency—both minimum bid price and market value—signals sustained market valuation pressure, likely reflecting clinical or operational uncertainty given NeuroSense’s late-stage biotech profile and lack of approved products. While the filing states the Company is evaluating actions aligned with long-term shareholder value, no specific remediation steps (e.g., reverse stock split, capital raise, strategic partnership) are disclosed. The forward-looking statements section explicitly identifies 'the ability of NeuroSense to remain listed on Nasdaq' as a material risk, reinforcing the centrality of this issue to the company’s near-term viability. Investors should monitor quarterly MVLS calculations and daily closing prices closely, particularly as the compliance window closes in late September 2026.